Bristol-Myers Squibb Co. (NYSE:BMY)‘s stock had its “hold” rating reissued by research analysts at Credit Suisse Group AG in a research note issued on Monday. They currently have a $58.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group AG’s target price would indicate a potential upside of 15.88% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, July 6th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a research report on Wednesday, July 13th. Berenberg Bank reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, July 12th. Citigroup Inc. cut their target price on shares of Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, August 3rd. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $85.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $69.06.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) opened at 50.05 on Monday. Bristol-Myers Squibb has a 12-month low of $49.10 and a 12-month high of $77.12. The stock has a 50 day moving average of $54.57 and a 200 day moving average of $66.13. The company has a market cap of $83.63 billion, a PE ratio of 29.27 and a beta of 0.74.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. The business earned $4.90 billion during the quarter, compared to the consensus estimate of $4.60 billion. During the same quarter in the previous year, the firm posted $0.53 EPS. The firm’s revenue was up 17.2% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb will post $2.63 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 7th will be paid a dividend of $0.38 per share. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.04%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 87.36%.

In other news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the transaction, the director now directly owns 334,499 shares of the company’s stock, valued at approximately $19,022,958.13. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.24% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Williams Jones & Associates LLC boosted its stake in shares of Bristol-Myers Squibb by 1.6% in the first quarter. Williams Jones & Associates LLC now owns 396,296 shares of the biopharmaceutical company’s stock worth $25,315,000 after buying an additional 6,125 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of Bristol-Myers Squibb by 9.8% in the first quarter. TIAA CREF Investment Management LLC now owns 10,372,071 shares of the biopharmaceutical company’s stock worth $662,568,000 after buying an additional 921,866 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of Bristol-Myers Squibb by 17.5% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 795,762 shares of the biopharmaceutical company’s stock worth $50,833,000 after buying an additional 118,308 shares during the last quarter. First Long Island Investors LLC boosted its stake in shares of Bristol-Myers Squibb by 1,160.0% in the first quarter. First Long Island Investors LLC now owns 63,000 shares of the biopharmaceutical company’s stock worth $4,024,000 after buying an additional 58,000 shares during the last quarter. Finally, Icon Advisers Inc. Co. boosted its stake in shares of Bristol-Myers Squibb by 95.3% in the first quarter. Icon Advisers Inc. Co. now owns 132,800 shares of the biopharmaceutical company’s stock worth $8,483,000 after buying an additional 64,800 shares during the last quarter. 72.87% of the stock is currently owned by institutional investors and hedge funds.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Receive News & Stock Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related stocks with our FREE daily email newsletter.